FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting If approved in the U.S. and EU, marstacimab could become the first once-weekly...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news